Junevity
Junevity develops therapeutics that aim to restore youthful cellular function and extend healthspan by resetting age-altered transcriptional programs. The company uses its RESET Platform — combining large-scale human transcriptomics, spatial transcriptomics, bioinformatics, and AI/ML — to identify transcription factor targets and design siRNA-based cell reprogramming therapeutics. Junevity's pipeline includes programs for metabolic and neurodegenerative indications and age-related diseases such as Type 2 Diabetes, Obesity, Osteoarthritis, and Sarcopenia. Operating as a biotechnology company serving research and drug-development partners, it applies computational and molecular tools to translate human disease data into first-in-class siRNA therapeutics.
Junevity
Junevity develops therapeutics that aim to restore youthful cellular function and extend healthspan by resetting age-altered transcriptional programs. The company uses its RESET Platform — combining large-scale human transcriptomics, spatial transcriptomics, bioinformatics, and AI/ML — to identify transcription factor targets and design siRNA-based cell reprogramming therapeutics. Junevity's pipeline includes programs for metabolic and neurodegenerative indications and age-related diseases such as Type 2 Diabetes, Obesity, Osteoarthritis, and Sarcopenia. Operating as a biotechnology company serving research and drug-development partners, it applies computational and molecular tools to translate human disease data into first-in-class siRNA therapeutics.